Vaginal bromocriptine in hyperprolactinemic patients and puerperal women

Acta Obstet Gynecol Scand. 1991;70(6):493-5. doi: 10.3109/00016349109007166.

Abstract

Fifteen hyperprolactinemic and 7 puerperal women were treated with bromocriptine per vaginam (2.5-5 mg) because of absolute intolerance to the oral administration of this drug. In both groups the prolactinemia was normalized without the typical side effects of bromocriptine. Three patients reported vaginal burning, but only one discontinued the therapy because of the intensity of the symptom. This study suggests that vaginal bromocriptine should be considered as a useful alternative for the treatment of hyperprolactinemia.

Publication types

  • Comparative Study

MeSH terms

  • Administration, Intravaginal
  • Adult
  • Bromocriptine / administration & dosage*
  • Bromocriptine / adverse effects
  • Bromocriptine / therapeutic use
  • Female
  • Humans
  • Hyperprolactinemia / drug therapy*
  • Lactation / drug effects*
  • Postpartum Period

Substances

  • Bromocriptine